Literature DB >> 8072943

Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.

M B Abdel-Naser1, S Krüger-Krasagakes, K Krasagakis, H Gollnick, A Abdel-Fattah, C E Orfanos.   

Abstract

Immunohistochemical and immunoserological evidence supports the involvement of both cell-mediated and humoral mechanisms in the pathogenesis of melanocyte destruction in vitiligo. Punch biopsies from depigmented vitiliginous skin (VS), normal-looking pigmented skin (PS), and marginal skin (MS) from patients with generalized vitiligo (n = 15) were labeled with K 1.2.58, OKM1 (CD11b), Leu 11b (CD16), Leu 19 (CD56), IFN-gamma receptor, IL-2 receptor (CD25), IgG, IgM, C3c, and C3d MoAbs. In addition, in vitro effects of vitiligo sera (n = 13) on human newborn melanocytes (HMel) under different culture conditions were studied. The immunohistochemical findings showed absence of K 1.2.58+ epidermal melanocytes in VS and abnormal morphology in MS. In these areas, a few CD11b+ cells in the dermis and epidermis could be detected but no significant numbers of CD16+ or CD56+ cells were seen among the mononuclear cellular infiltrate. IL-2 and IFN-gamma receptors were clearly expressed by the cellular infiltrate. No significant deposition of complement or immunoglobulin was seen. The addition of vitiligo sera to HMel cultures induced a significant cellular proliferation. The stimulation of cell proliferation occurred regardless whether the sera were added alone or when preheated (56 degrees C for 1 hr) and then supplemented with a complement source (P < 0.01 at 2%, P < 0.001 at 10%, and P < 0.01 at 20% for sera alone) (P > 0.05 at 2%, P < 0.05 at 10%, and P < 0.01 at 20% for decomplemented sera plus complement).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8072943     DOI: 10.1111/j.1600-0749.1994.tb00013.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  9 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

3.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.

Authors:  I C Le Poole; R M van den Wijngaard; W Westerhof; P K Das
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 4.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro.

Authors:  K Krasagakis; C Garbe; J Eberle; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy.

Authors:  Belinda Palermo; Silvia Garbelli; Stefania Mantovani; Claudia Giachino
Journal:  J Autoimmune Dis       Date:  2005-08-31

7.  Aspirin in dermatology: Revisited.

Authors:  Aditya Kumar Bubna
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

8.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

Review 9.  Vitiligo in Children: A Review of Conventional Treatments.

Authors:  Serena Gianfaldoni; Uwe Wollina; Georgi Tchernev; Jacopo Lotti; Katlein França; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2018-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.